

To Our Shareholders

Gyo Sagara  
President, Representative Director & CEO  
Ono Pharmaceutical Co., Ltd.  
1-5, Doshomachi 2-chome, Chuo-ku, Osaka, Japan  
Head Office:  
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan

NOTICE OF RESOLUTIONS PASSED  
AT THE 75TH ORDINARY GENERAL SHAREHOLDERS' MEETING

We hereby inform you that the matters below were reported and resolved at the 75th Ordinary General Shareholders' Meeting of Ono Pharmaceutical Co., Ltd. (hereinafter "We" or the "Company") held on June 22, 2023.

**Matters reported:**

1. Business Report and Consolidated Financial Statements for the 75th Fiscal Year (from April 1, 2022 to March 31, 2023), as well as the Audit Report on the Consolidated Financial Statements for the 75th Fiscal Year by the Accounting Auditor and the Audit & Supervisory Board
2. Non-Consolidated Financial Statements for the 75th Fiscal Year (from April 1, 2022 to March 31, 2023)

The contents of above matters were duly reported.

**Matters resolved:**

**Proposal 1:** Appropriation of Surplus

This matter was approved as originally proposed. The year-end dividend is ¥37 per share, and this makes the total annual dividend ¥70 per share, together with the interim dividend (an increase of ¥14 per share compared to the previous fiscal year). Friday, June 23, 2023 was set as the effective date of the distribution of the dividend.

**Proposal 2:** Election of Seven (7) Members of the Board of Directors

This matter was approved as originally proposed. Seven (7) Members of the Board of Directors, namely, Gyo Sagara, Toshihiro Tsujinaka, Toichi Takino, Kiyooki Idemitsu, Masao Nomura, Akiko Okuno and Shusaku Nagae were reelected and each of them assumed their respective offices. Masao Nomura, Akiko Okuno and Shusaku Nagae are Outside Directors.

**Proposal 3:** Election of Two (2) Audit & Supervisory Board Members

This matter was approved as originally proposed. Two (2) Audit & Supervisory Board Members, namely, Hironobu Tanisaka and Akiko Tanabe were reelected and each of them assumed their respective offices. Akiko Tanabe is an Outside Audit & Supervisory Board Member.

**Proposal 4:** Revision to the Amount of Remuneration for Audit & Supervisory Board Members

This matter was approved as originally proposed. The maximum amount of remuneration for Audit & Supervisory Board Members was revised to ¥150 million per year.

### Notice of Personnel Change in Officers

The Officers of the Company on and after June 22, 2023 were determined as follows.

<b>Members of the Board of Directors</b>		<b>Corporate Officers</b> (who are not serving concurrently as Members of the Board of Directors)	
President & CEO Representative Director	Gyo Sagara	Executive Officer	Satoshi Numata
Member of the Board of Directors Senior Executive Officer	Toshihiro Tsujinaka	Executive Officer	Akira Takada
Member of the Board of Directors Senior Executive Officer	Toichi Takino	Executive Officer	Satoshi Takahagi
Member of the Board of Directors Executive Officer	Kiyooki Idemitsu	Corporate Officer	Hiromu Habashita
Outside Director	Masao Nomura	Corporate Officer	Shinji Takai
Outside Director	Akiko Okuno	Corporate Officer	Masaki Ito
Outside Director	Shusaku Nagae	Corporate Officer	Tatsuya Okamoto
<b>Audit &amp; Supervisory Board Members</b>		Corporate Officer	Masayuki Tanigawa
Full-time Audit & Supervisory Board Member	Katsuyoshi Nishimura	Corporate Officer	Takehiro Yamada
Full-time Audit & Supervisory Board Member	Hironobu Tanisaka		
Outside Audit & Supervisory Board Member	Yasuo Hishiyama		
Outside Audit & Supervisory Board Member	Akiko Tanabe		

All officers will make ongoing united efforts toward the further growth of the Company's business, and would appreciate the continued support and cooperation of our shareholders.

### Notice Regarding the Payment of Year-End Dividend

Please receive the year-end cash dividend for the 75th fiscal year (¥37 per share) with the enclosed "Cash Dividend Receipt" during the payout period (from Friday, June 23, 2023 to Monday, July 31, 2023).

If you opt to receive dividend by bank transfer, please confirm the enclosed "Dividend Statement" and "Designation of Bank Account." If you opt for distribution in proportion to the number of shares held, please confirm the enclosed "Dividend Statement" and "Information on Methods to Receive Dividend."

---

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.